944396-07-0

Basic information

• Product Name: BKM120 (NVP-BKM120, Buparlisib)
• Synonyms: 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine;NVP-BKM-120;5-(2,6-diMorpholinopyriMidin-4-yl)-4-(trifluoroMethyl)pyridin-2-aMine;BKM120 (NVP-BKM120);BKM120 (NVP-BKM120, Buparlisib);NVP-BKM120, Buparlisib;BKM120BASE;Buparlisib
• CAS NO: 944396-07-0
• Molecular Formula: C18H21F3N6O2
• Molecular Weight: 410.3935496
• Product Categories: API;Inhibitor;Inhibitors;Akt;mTOR;PI3K
• Mol File: 944396-07-0.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 645.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.382
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (15 mg/ml)
• PKA: 5.94±0.50(Predicted)
• Stability: Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: BKM120 (NVP-BKM120, Buparlisib)(CAS DataBase Reference)
• NIST Chemistry Reference: BKM120 (NVP-BKM120, Buparlisib)(944396-07-0)
• EPA Substance Registry System: BKM120 (NVP-BKM120, Buparlisib)(944396-07-0)

Safety Data

• Hazardous Substances Data: 944396-07-0(Hazardous Substances Data)

Usage

Description

BKM120 (NVP-BKM120, Buparlisib) is a potent pan-Class I PI3-kinase inhibitor with selective activity against PI3 kinase, which plays a crucial role in cell growth, proliferation, and survival. It has demonstrated significant anti-tumor effects, particularly in glioma cells that originate from tumors in the brain or spine.

Uses

Used in Oncology:
BKM120 (NVP-BKM120, Buparlisib) is used as an anti-tumor agent for the treatment of glioma cells. It specifically inhibits PI3 kinase, leading to cell death in these cancerous cells. This selective action makes it a promising therapeutic option for patients with brain or spinal tumors.
Additionally, Buparlisib has shown a significant reduction in DNA synthesis in a mouse model of BRCA1-linked triple-negative breast cancer, with minimal effects on normal tissue. This suggests its potential use in targeted cancer therapies for specific genetic mutations.
While the provided materials do not explicitly mention other industries, the primary focus of BKM120 (NVP-BKM120, Buparlisib) is in the field of oncology for its anti-tumor properties. Further research and development may reveal additional applications in different industries.

References

Burger et al. (2011), Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer; ACS Med. Chem. Lett. 2 774 Maira et al. (2012), Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor; Mol. Cancer Ther. 11 317 Brachmann et al. (2012), Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations; Mol. Cancer Ther. 11 1747 Juvekar et al. (2016), Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion; Proc. Natl. Acad. Sci USA. 113 E4338

Downstream Products

• 1619969-45-7 N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide